When is the next results date for Ambey?

No Upcoming Board Meetings

Has Ambey declared dividend?

No Dividend History Available

What is the technical trend for Ambey?

As of May 19, 2025, Ambey's technical trend is mildly bearish, influenced by daily moving averages and OBV, despite a mildly bullish weekly MACD.

As of 19 May 2025, the technical trend for Ambey has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the daily moving averages and Bollinger Bands are both showing mildly bearish signals. The weekly KST is bearish, and the OBV is also mildly bearish. The Dow Theory shows no trend in both weekly and monthly time frames. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the OBV.

Who are the peers of the Ambey Laborator.?

Ambey Laborator.'s peers include Punjab Chemicals, Heranba Inds, Best Agrolife, Shivalik Rasayan, Crop Life Science, Aristo Bio-Tech, Dharmaj Crop, Aimco Pesticides, and Bhaskar Agrochem. Ambey Laborator. has good management risk but below average growth and a significant negative return of -56.40%, the lowest among its peers.

Peers: The peers of Ambey Laborator. are Punjab Chemicals, Heranba Inds, Best Agrolife, Shivalik Rasayan, Crop Life Scienc, Aristo Bio-Tech, Dharmaj Crop, Aimco Pesticides, and Bhaskar Agrochem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Best Agrolife, while Good management risk is found at Ambey Laborator. and the rest. Average management risk is noted at Punjab Chemicals, Heranba Inds, Crop Life Scienc, Dharmaj Crop, Aimco Pesticides, and Bhaskar Agrochem. Below Average management risk is present at Shivalik Rasayan and Aristo Bio-Tech. In terms of growth, Good growth is seen at Best Agrolife, while Average growth is noted at Dharmaj Crop and the rest. Below Average growth is observed at Ambey Laborator., Punjab Chemicals, Heranba Inds, Shivalik Rasayan, Crop Life Scienc, Aristo Bio-Tech, Aimco Pesticides, and Bhaskar Agrochem. For capital structure, Excellent capital structure is found at Shivalik Rasayan, Good at Punjab Chemicals and Dharmaj Crop, Average at Ambey Laborator., Crop Life Scienc, Best Agrolife, Aimco Pesticides, and the rest, and Below Average at Aristo Bio-Tech and Bhaskar Agrochem.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aristo Bio-Tech at 28.67%, while Ambey Laborator. has the lowest at -56.40%. Ambey Laborator.'s return is significantly lower than all peers. Additionally, the six-month return is negative for Ambey Laborator., Best Agrolife, Shivalik Rasayan, and Bhaskar Agrochem.

What does Ambey Laborator. do?

Ambey Laboratories Ltd operates in the Pesticides & Agrochemicals industry as a Micro Cap company, with a market cap of INR 95 Cr. It was incorporated in 1985 and has a P/E ratio of 21.00, with no recent revenue or profit data available.

Overview:<BR>Ambey Laboratories Ltd operates in the Pesticides & Agrochemicals industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Ambey Laboratories Ltd was originally incorporated as "Ambey Laboratories Private Limited" in 1985. It later converted to a Public Limited Company and changed its name to "Ambey Laboratories Limited" on December 30, 2014. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 95 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00<BR>Industry P/E: 40<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.90<BR>Return on Equity: 15.17%<BR>Price-to-Book: 3.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Ambey Laborator.?

The top shareholder of Ambey Laborator is Sarina Gupta, holding 68.49% of the shares, with no pledged promoter holdings. Public shareholders include Nakshatra Stressed Assets Fund Scheme I at 1.65% and individual investors collectively holding 22.4%.

The top shareholders of Ambey Laborator are primarily the promoters, with Sarina Gupta holding the highest stake at 68.49%. There are no pledged promoter holdings. In terms of public shareholders, the highest is Nakshatra Stressed Assets Fund Scheme I, which holds 1.65%. Additionally, individual investors collectively hold 22.4% of the shares. There is also one foreign institutional investor (FII) with a very small holding of 0.01%.

How big is Ambey Laborator.?

As of 24th July, Ambey Laboratories Ltd has a market capitalization of 115.00 Cr, classifying it as a Micro Cap company, with no available financial data for Net Sales and Net Profit for the latest four quarters. The balance sheet as of March 2024 shows Shareholder's Funds of 31.51 Cr and Total Assets of 76.74 Cr.

As of 24th July, <BR><BR>Market Cap: Ambey Laboratories Ltd has a market capitalization of 115.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 31.51 Cr and Total Assets totaling 76.74 Cr.

Is Ambey Laborator. overvalued or undervalued?

As of September 23, 2025, Ambey Laborator is considered very expensive and overvalued with a PE Ratio of 21.92 and an EV to EBITDA of 15.02, significantly underperforming with a -39.55% return compared to the Sensex's -2.97%.

As of 23 September 2025, the valuation grade for Ambey Laborator. has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE Ratio of 21.92, an EV to EBITDA of 15.02, and a ROE of 6.26%. <BR><BR>In comparison to its peers, UPL has a PE Ratio of 38.05 and an EV to EBITDA of 9.17, while P I Industries is also very expensive with a PE of 34.2 and an EV to EBITDA of 24.36. Ambey Laborator.'s valuation appears stretched relative to these peers, highlighting its overvaluation status. Notably, over the past year, the stock has underperformed with a return of -39.55%, contrasting sharply with the Sensex's decline of only -2.97%.

How has been the historical performance of Ambey Laborator.?

Ambey Laborator has shown steady growth in net sales, increasing from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25, but faced a decline in profit after tax to 4.78 Cr in Mar'25. The company has negative cash flow from operating activities, indicating liquidity challenges, despite a significant inflow from financing activities.

Answer:<BR>The historical performance of Ambey Laborator shows a steady growth in net sales and total operating income over the past four years, with figures rising from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25. The total expenditure has also increased, reflecting higher raw material costs, which rose from 69.91 Cr in Mar'22 to 118.83 Cr in Mar'25. Operating profit, excluding other income, has fluctuated slightly, peaking at 11.50 Cr in Mar'25, while profit before tax increased to 6.04 Cr in the same period. However, profit after tax saw a decline to 4.78 Cr in Mar'25 from 7.72 Cr in Mar'24. The company's equity capital has grown significantly, reaching 24.95 Cr in Mar'25, and total liabilities increased to 125.79 Cr, driven by a rise in short-term borrowings. Cash flow from operating activities has been negative, indicating challenges in cash generation, while cash flow from financing activities has provided a net inflow of 48.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Ambey Laborator's financial performance has demonstrated a consistent upward trend in net sales, which increased from 84.60 Cr in Mar'22 to 131.27 Cr in Mar'25, alongside total operating income that mirrored this growth. The company's total expenditure also rose, primarily due to escalating raw material costs, which climbed from 69.91 Cr to 118.83 Cr over the same period. Operating profit, despite some fluctuations, reached 11.50 Cr in Mar'25, contributing to a profit before tax of 6.04 Cr. However, profit after tax decreased to 4.78 Cr in Mar'25, down from the previous year's 7.72 Cr. The equity capital has notably increased to 24.95 Cr, while total liabilities surged to 125.79 Cr, largely due to a significant rise in short-term borrowings. The cash flow from operating activities has been negative, indicating potential liquidity issues, although cash flow from financing activities has provided a substantial inflow, reflecting the company's reliance on external financing to support its operations.

Which are the latest news on Ambey Laborator.?

Why is Ambey Laborator. falling/rising?

As of 04-Dec, Ambey Laboratories Ltd's stock price is at 40.55, reflecting a decline of 4.92%. The stock has underperformed against the Sensex and shows a significant year-to-date drop of 36.39%, with reduced investor interest indicated by a sharp decrease in trading volume.

As of 04-Dec, Ambey Laboratories Ltd's stock price is falling, currently at 40.55, which reflects a decrease of 2.1 or 4.92%. The stock has underperformed compared to the benchmark Sensex, which has only declined by 0.69% over the past week. Over the last month, while the stock has seen a slight increase of 3.97%, its year-to-date performance shows a significant decline of 36.39%, contrasting sharply with the Sensex's gain of 10.10%.<BR><BR>Today's performance indicates that the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests a persistent downward trend. Additionally, there has been a notable drop in investor participation, with delivery volume on December 3rd falling by 80% compared to the 5-day average. This decline in trading activity further supports the stock's downward movement, indicating reduced interest among investors. Overall, these factors contribute to the current decline in Ambey Laboratories Ltd's stock price.